Coordinated by Inserm, the European project OBERON aims to develop panels of tests that will – eventually – make it possible to determine with more accuracy and certitude how compounds suspected of being endocrine disruptors might induce metabolic disorders and, ultimately, to identify these compounds.
The OBERON project has started on 1st January 2019.
OBERON Kick-Off Meeting took place on the 8st of February 2019 in Brussels, Belgium. This meeting gathered all 11 partners from 6 countries for presenting the planned work program.
Joint Launch Event of Projects from the Call ‘New Testing and Screening Methods to Identify Endocrine Disrupting Chemicals’ The current testing tools, including regulatory in vivo tests and novel in vitro assays, do not appropriately identify effects related to certain less studied endocrine-mediated pathways or health outcomes, in which endocrine disruptors may be implicated. The focus of proposals should Read the full article…
Download presentation leaflet